Cite
HARVARD Citation
McDermott, D. et al. (2021). Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma. Journal of clinical oncology. 39 (9), pp. 1029-1039. [Online].